Novacyt (ALNOV) - Net Assets

Latest as of December 2025: €23.34 Million EUR ≈ $27.29 Million USD

Based on the latest financial reports, Novacyt (ALNOV) has net assets worth €23.34 Million EUR (≈ $27.29 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€40.28 Million ≈ $47.09 Million USD) and total liabilities (€16.94 Million ≈ $19.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Novacyt's equity to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€23.34 Million
% of Total Assets	57.94%
Annual Growth Rate	N/A
5-Year Change	-83.54%
10-Year Change	54.1%
Growth Volatility	343.89

Novacyt - Net Assets Trend (2008–2025)

This chart illustrates how Novacyt's net assets have evolved over time, based on quarterly financial data. See ALNOV cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Novacyt (2008–2025)

The table below shows the annual net assets of Novacyt from 2008 to 2025. For live valuation and market cap data, see ALNOV market cap.

Year	Net Assets	Change
2025-12-31	€23.34 Million ≈ $27.29 Million	-51.26%
2024-12-31	€47.88 Million ≈ $55.98 Million	-45.12%
2023-12-31	€87.24 Million ≈ $102.00 Million	-24.28%
2022-12-31	€115.22 Million ≈ $134.70 Million	-18.76%
2021-12-31	€141.81 Million ≈ $165.80 Million	-5.90%
2020-12-31	€150.71 Million ≈ $176.20 Million	+1108.76%
2019-12-31	€12.47 Million ≈ $14.58 Million	-31.32%
2018-12-31	€18.15 Million ≈ $21.22 Million	-17.92%
2017-12-31	€22.12 Million ≈ $25.86 Million	+46.03%
2016-12-31	€15.15 Million ≈ $17.71 Million	+95.00%
2015-12-31	€7.77 Million ≈ $9.08 Million	-51.57%
2014-12-31	€16.04 Million ≈ $18.75 Million	+726.35%
2013-12-31	€1.94 Million ≈ $2.27 Million	+44.75%
2012-12-31	€1.34 Million ≈ $1.57 Million	+280.02%
2011-12-31	€-744.73K ≈ $-870.67K	+11.97%
2010-12-31	€-846.00K ≈ $-989.06K	-29.36%
2009-12-31	€-654.00K ≈ $-764.59K	-148.67%
2008-12-31	€-263.00K ≈ $-307.47K	--

Equity Component Analysis

This analysis shows how different components contribute to Novacyt's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 5061008503.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	€4.05 Million	17.35%
Other Comprehensive Income	€21.70 Million	92.98%
Other Components	€50.48 Million	216.31%
Total Equity	€23.34 Million	100.00%

Novacyt Competitors by Market Cap

The table below lists competitors of Novacyt ranked by their market capitalization.

Company	Market Cap
Co2 Capsol AS OL:CAPSL	$33.39 Million
Kartal Yenilenebilir Enerji Uretim AS IS:KARYE	$33.43 Million
Freemelt Holding AB ST:FREEM	$33.44 Million
Mindax Ltd AU:MDX	$33.44 Million
Avonmore Capital & Management Services Limited NSE:AVONMORE	$33.36 Million
Manx Financial Group PLC F:3IM	$33.35 Million
KNW Co. Ltd KQ:105330	$33.32 Million
Fusemachines Inc. Common stock NASDAQ:FUSE	$33.28 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Novacyt's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 47,880,000 to 23,338,742, a change of -24,541,258 (-51.3%).
Net loss of 23,311,024 reduced equity.
Share repurchases of 17,317 reduced equity.
Other comprehensive income increased equity by 21,700,234.
Other factors decreased equity by 22,913,151.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	€-23.31 Million	-99.88%
Share Repurchases	€17.32K	-0.07%
Other Comprehensive Income	€21.70 Million	+92.98%
Other Changes	€-22.91 Million	-98.18%
Total Change	€-	-51.26%

Book Value vs Market Value Analysis

This analysis compares Novacyt's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.19x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2011-12-31	€-0.28	€0.39	x
2012-12-31	€0.50	€0.39	x
2013-12-31	€0.66	€0.39	x
2014-12-31	€3.61	€0.39	x
2015-12-31	€1.14	€0.39	x
2016-12-31	€1.25	€0.39	x
2017-12-31	€0.96	€0.39	x
2018-12-31	€0.48	€0.39	x
2019-12-31	€0.27	€0.39	x
2020-12-31	€2.21	€0.39	x
2021-12-31	€2.01	€0.39	x
2022-12-31	€1.63	€0.39	x
2023-12-31	€1.24	€0.39	x
2024-12-31	€0.68	€0.39	x
2025-12-31	€0.33	€0.39	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Novacyt utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -99.88%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -114.25%
• Asset Turnover: 0.51x
• Equity Multiplier: 1.73x
Recent ROE (-99.88%) is below the historical average (-32.60%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	0.00%	-74.93%	0.61x	0.00x	€-497.11K
2012	-33.95%	-50.47%	0.27x	2.46x	€-589.29K
2013	-42.86%	-82.67%	0.38x	1.37x	€-1.03 Million
2014	-18.03%	-81.72%	0.17x	1.30x	€-4.50 Million
2015	-132.14%	-156.41%	0.52x	1.63x	€-11.04 Million
2016	-32.14%	-51.55%	0.36x	1.71x	€-6.38 Million
2017	-21.84%	-36.39%	0.44x	1.37x	€-7.04 Million
2018	-23.53%	-34.53%	0.42x	1.61x	€-6.09 Million
2019	-26.74%	-29.83%	0.42x	2.13x	€-4.58 Million
2020	87.87%	47.77%	1.18x	1.55x	€117.35 Million
2021	-6.86%	-10.16%	0.52x	1.30x	€-23.91 Million
2022	-19.27%	-105.52%	0.15x	1.22x	€-33.72 Million
2023	-32.43%	-244.34%	0.09x	1.53x	€-37.02 Million
2024	-87.21%	-212.73%	0.28x	1.48x	€-46.55 Million
2025	-99.88%	-114.25%	0.51x	1.73x	€-25.64 Million

Industry Comparison

This section compares Novacyt's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $19,365,365
Average return on equity (ROE) among peers: -141.14%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Novacyt (ALNOV)	€23.34 Million	0.00%	0.73x	$33.38 Million
Affluent Medical SAS (AFME)	$31.47 Million	-49.74%	0.80x	$110.43 Million
Biosynex (ALBIO)	$66.29 Million	47.32%	0.90x	$15.74 Million
Bluelinea SA (ALBLU)	$2.68 Million	-60.39%	3.04x	$9.00 Million
Carmat (ALCAR)	$1.40 Million	-1250.42%	5.16x	$6.37 Million
Diagnostic Medical Systems SA (ALDMS)	$25.27 Million	-10.60%	0.84x	$34.47 Million
Eurobio Scientific SA (ALERS)	$18.07 Million	-40.63%	1.08x	$236.10 Million
Ikonisys SA (ALIKO)	$15.73 Million	-14.41%	0.33x	$21.30 Million
Implanet SA (ALIMP)	$-174.00K	0.00%	0.00x	$28.16 Million
Mediantechn (ALMDT)	$-7.25 Million	0.00%	0.00x	$183.29 Million
Mauna Kea Technologies SAS (ALMKT)	$40.16 Million	-32.51%	0.22x	$28.43 Million

About Novacyt

PA:ALNOV France Medical Devices

Market Cap

$33.38 Million

€28.55 Million EUR

Market Cap Rank

#23460 Global

#372 in France

Share Price

€0.39

Change (1 day)

-3.43%

52-Week Range

€0.32 - €0.90

All Time High

€13.24